LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.03 2.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.95

Max

2.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

13M

19M

Pardavimai

4.7M

38M

P/E

Sektoriaus vid.

5.605

56.602

Pelnas, tenkantis vienai akcijai

0.23

Pelno marža

49.552

Darbuotojai

119

EBITDA

14M

18M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.05% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

121M

172M

Ankstesnė atidarymo kaina

-0.5

Ankstesnė uždarymo kaina

2.03

Naujienos nuotaikos

By Acuity

55%

45%

319 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-16 19:39; UTC

Pagrindinės rinkos jėgos

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

2025-05-16 23:18; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025-05-16 22:30; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- Update

2025-05-16 21:56; UTC

Rinkos pokalbiai

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025-05-16 21:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-16 21:54; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025-05-16 21:22; UTC

Rinkos pokalbiai

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025-05-16 21:17; UTC

Rinkos pokalbiai

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025-05-16 21:17; UTC

Svarbiausios naujienos

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025-05-16 21:05; UTC

Rinkos pokalbiai

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025-05-16 20:55; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-16 20:37; UTC

Svarbiausios naujienos

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025-05-16 20:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025-05-16 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025-05-16 20:18; UTC

Svarbiausios naujienos

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025-05-16 20:16; UTC

Svarbiausios naujienos

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025-05-16 20:15; UTC

Uždarbis

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025-05-16 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: William K. Daniel Joins Board

2025-05-16 20:10; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: Strategic Investment by KKR Completed

2025-05-16 20:05; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 19:38; UTC

Rinkos pokalbiai

Oil Futures Post Second Straight Weekly Gain -- Market Talk

2025-05-16 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2025-05-16 18:51; UTC

Svarbiausios naujienos

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

2025-05-16 18:41; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 18:37; UTC

Rinkos pokalbiai

Gold Futures End Week on Negative Note -- Market Talk

2025-05-16 18:35; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

2025-05-16 18:32; UTC

Svarbiausios naujienos

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

2025-05-16 18:28; UTC

Rinkos pokalbiai

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

26.05% į viršų

12 mėnesių prognozė

Vidutinis 3 USD  26.05%

Aukščiausias 3.5 USD

Žemiausias 2.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

319 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.